11:10 AM
Oct 06, 2017
 |  BC Week In Review  |  Financial News  |  Completed Offerings

KSQ debuts with $76M financing

On Oct. 2, CRISPR-associated protein 9 (Cas9)-based therapeutic company KSQ Therapeutics Inc. (Cambridge, Mass.) emerged from stealth with a $76 million financing led by Flagship Pioneering, with participation from Polaris Partners, Arch Venture Partners and Alexandria Equities. The company said the funding is spread across a series A and B round but declined to break...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >